For $1.3 billion in aggregate—including upfront and milestone payments—Bayer will get exclusive global access to Kumquat ...

Berlin: Bayer and Kumquat Biosciences Inc., a clinical-stage biotech company, have announced that they have entered into an ...

Bayer and Kumquat Biosciences have entered an exclusive global license and collaboration to develop and commercialize Kumquat ...

Bayer has teamed up with Kumquat Biosciences for a juicy opportunity, committing up to $1.3 billion for the global license to ...

Bayer partners with Kumquat Biosciences to advance a promising Kras G12D cancer treatment, aiming to address critical unmet ...

New clinical data reveals promising efficacy of VS-7375, a KRAS G12D inhibitor, in advanced lung cancer, highlighting its ...

Bayer will partner with Kumquat Biosciences to develop Kumquat’s KRAS G12D inhibitor, which could generate $1.3 billion-plus for the San Diego biotech.

The data, which will be presented at the IASLC 2025 World Conference on Lung Cancer in Barcelona, builds upon earlier results presented at ASCO. The study showed a disease control rate of 93.8% at the ...

An off-the-shelf cancer vaccine that targets KRAS mutations induced T-cell responses and was associated with impressive ...

The deal – which has a total value of up to $1.3 billion including an unspecified upfront payment – gives Bayer exclusive ...

Under the global exclusive license deal, Kumquat will be responsible for the Phase 1a study of its inhibitor and Bayer will ...

Bayer and Kumquat Biosciences have signed an exclusive global license and collaboration to develop a KRAS G12D inhibitor, ...